Viking Therapeutics (VKTX) EBT (2014 - 2026)
Viking Therapeutics (VKTX) reported EBT of -$266.4 million for Q1 2026, down 119.6% on a YoY basis from $1.4 billion in Q1 2025, and up 4.44% sequentially from -$278.7 million in Q4 2025.
Viking Therapeutics (VKTX) EBT (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of EBT data on file, last reported at -$266.4 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 119.6% year-over-year to -$266.4 million; the trailing twelve-month figure through Mar 2026 stood at -$869.3 million (down 1.47% YoY), and the FY2025 full-year result was -$506.2 million, down 60.63% from the prior year.
- EBT grew to -$266.4 million in Q1 2026, from -$278.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$17.8 million in Q3 2022 to a low of -$60.3 billion in Q1 2023.
- A 5-year average of -$8.0 billion and a median of -$189.8 million in 2024 frame the typical range for EBT.
- Across the five-year window, EBT slumped 318707.31% in 2023 and jumped 99.48% in 2024, its largest moves.
- Tracing VKTX's EBT over 5 years: stood at -$40.3 million in 2022, then plunged by 126.06% to -$91.1 million in 2023, then sank by 108.42% to -$189.8 million in 2024, then slumped by 46.87% to -$278.7 million in 2025, then advanced by 4.44% to -$266.4 million in 2026.
- Business Quant data shows VKTX's EBT at -$266.4 million in Q1 2026, -$278.7 million in Q4 2025, and -$173.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Viking Therapeutics | 4.03 Bn | 4.03 Bn | - | -266.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266.38 Mn |
| Dec 31, 2025 | -278.75 Mn |
| Sep 30, 2025 | -173.02 Mn |
| Jun 30, 2025 | -151.16 Mn |
| Mar 31, 2025 | -121.30 Mn |
| Dec 31, 2024 | -189.79 Mn |
| Sep 30, 2024 | -288.03 Mn |
| Jun 30, 2024 | -257.58 Mn |
| Mar 31, 2024 | -436.20 Mn |
| Dec 31, 2023 | -91.06 Mn |
| Sep 30, 2023 | -23.36 Bn |
| Jun 30, 2023 | -49.62 Bn |
| Mar 31, 2023 | -60.35 Bn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -17.85 Mn |
| Jun 30, 2022 | -19.45 Mn |
| Mar 31, 2022 | -18.93 Mn |
| Dec 31, 2021 | -15.77 Mn |
| Sep 30, 2021 | -18.95 Mn |
| Jun 30, 2021 | -20.59 Mn |